 Nichole Carlson
Concepts (522)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis, Pulmonary | 3 | 2025 | 83 | 1.510 |
Why?
| | Bayes Theorem | 6 | 2020 | 374 | 1.250 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 178 | 1.080 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2503 | 1.050 |
Why?
| | Models, Statistical | 6 | 2020 | 624 | 1.000 |
Why?
| | Sarcoidosis | 2 | 2025 | 157 | 0.960 |
Why?
| | Hydrocortisone | 6 | 2015 | 306 | 0.900 |
Why?
| | Outpatients | 7 | 2024 | 375 | 0.860 |
Why?
| | Hormones | 3 | 2017 | 140 | 0.830 |
Why?
| | Emphysema | 1 | 2023 | 109 | 0.780 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 180 | 0.730 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 275 | 0.690 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 739 | 0.680 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 337 | 0.670 |
Why?
| | Diabetes Complications | 1 | 2022 | 219 | 0.670 |
Why?
| | Radiography, Thoracic | 2 | 2024 | 165 | 0.640 |
Why?
| | Disease Susceptibility | 1 | 2021 | 333 | 0.610 |
Why?
| | Metadata | 1 | 2018 | 9 | 0.600 |
Why?
| | Computer Simulation | 4 | 2017 | 937 | 0.570 |
Why?
| | State Health Plans | 2 | 2008 | 29 | 0.570 |
Why?
| | Models, Biological | 3 | 2017 | 1717 | 0.550 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 237 | 0.540 |
Why?
| | Ovary | 3 | 2017 | 209 | 0.540 |
Why?
| | Genome | 1 | 2018 | 278 | 0.510 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 133 | 0.510 |
Why?
| | Reproduction | 1 | 2017 | 198 | 0.500 |
Why?
| | Residence Characteristics | 6 | 2010 | 331 | 0.490 |
Why?
| | Child Health Services | 2 | 2008 | 182 | 0.490 |
Why?
| | Humans | 93 | 2025 | 129527 | 0.470 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 17 | 0.460 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 566 | 0.460 |
Why?
| | Software | 2 | 2019 | 608 | 0.460 |
Why?
| | Brain Injuries | 5 | 2010 | 469 | 0.450 |
Why?
| | Health Services for the Aged | 2 | 2019 | 72 | 0.450 |
Why?
| | Biometry | 2 | 2017 | 69 | 0.450 |
Why?
| | Obesity | 12 | 2023 | 2875 | 0.440 |
Why?
| | Computational Biology | 1 | 2018 | 591 | 0.440 |
Why?
| | Female | 72 | 2025 | 68650 | 0.440 |
Why?
| | Circadian Rhythm | 4 | 2013 | 416 | 0.430 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 28 | 0.420 |
Why?
| | Adult | 52 | 2024 | 35505 | 0.420 |
Why?
| | Pulsatile Flow | 1 | 2013 | 60 | 0.410 |
Why?
| | Environment Design | 3 | 2010 | 26 | 0.410 |
Why?
| | Health Services Accessibility | 4 | 2010 | 897 | 0.410 |
Why?
| | Antibodies, Viral | 5 | 2024 | 602 | 0.410 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 51 | 0.400 |
Why?
| | Aged | 27 | 2024 | 22063 | 0.390 |
Why?
| | Middle Aged | 37 | 2025 | 31087 | 0.370 |
Why?
| | Specimen Handling | 1 | 2013 | 163 | 0.370 |
Why?
| | Saliva | 1 | 2013 | 212 | 0.360 |
Why?
| | Gonadotropins | 3 | 2023 | 38 | 0.360 |
Why?
| | Walking | 4 | 2010 | 491 | 0.350 |
Why?
| | Alzheimer Disease | 4 | 2023 | 516 | 0.350 |
Why?
| | Male | 44 | 2025 | 63586 | 0.340 |
Why?
| | White Matter | 2 | 2023 | 135 | 0.340 |
Why?
| | Lung | 5 | 2025 | 3928 | 0.330 |
Why?
| | Levodopa | 2 | 2007 | 30 | 0.330 |
Why?
| | Hypogonadism | 2 | 2015 | 84 | 0.330 |
Why?
| | Oregon | 8 | 2011 | 68 | 0.330 |
Why?
| | Hospitalization | 8 | 2024 | 2076 | 0.330 |
Why?
| | Activities of Daily Living | 3 | 2010 | 385 | 0.320 |
Why?
| | Parkinson Disease | 4 | 2009 | 462 | 0.320 |
Why?
| | Endocrine System | 1 | 2009 | 20 | 0.320 |
Why?
| | Testosterone | 2 | 2010 | 371 | 0.310 |
Why?
| | Technology | 1 | 2009 | 86 | 0.290 |
Why?
| | Estradiol | 6 | 2023 | 492 | 0.290 |
Why?
| | Prenatal Care | 1 | 2010 | 277 | 0.290 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 50 | 0.280 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2421 | 0.280 |
Why?
| | Levonorgestrel | 4 | 2011 | 37 | 0.280 |
Why?
| | Health Behavior | 3 | 2010 | 742 | 0.280 |
Why?
| | Cognition Disorders | 3 | 2008 | 505 | 0.280 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.280 |
Why?
| | Young Adult | 15 | 2024 | 12438 | 0.270 |
Why?
| | Perception | 2 | 2007 | 346 | 0.270 |
Why?
| | Antibodies, Monoclonal | 5 | 2024 | 1366 | 0.270 |
Why?
| | Methylphenidate | 1 | 2007 | 36 | 0.270 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 55 | 0.260 |
Why?
| | Smoking Cessation | 1 | 2010 | 409 | 0.260 |
Why?
| | Aged, 80 and over | 11 | 2021 | 7052 | 0.250 |
Why?
| | Time Factors | 13 | 2017 | 6530 | 0.250 |
Why?
| | Longitudinal Studies | 10 | 2020 | 2724 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3622 | 0.240 |
Why?
| | Poverty | 2 | 2010 | 497 | 0.230 |
Why?
| | Cluster Analysis | 2 | 2023 | 483 | 0.230 |
Why?
| | Gliosis | 2 | 2023 | 28 | 0.230 |
Why?
| | Healthcare Disparities | 1 | 2010 | 579 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2024 | 56 | 0.220 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 63 | 0.220 |
Why?
| | Medicaid | 1 | 2008 | 418 | 0.210 |
Why?
| | Alanine | 1 | 2024 | 143 | 0.210 |
Why?
| | Denmark | 2 | 2021 | 45 | 0.210 |
Why?
| | Retrospective Studies | 13 | 2024 | 14532 | 0.210 |
Why?
| | Risk Factors | 10 | 2022 | 9779 | 0.210 |
Why?
| | Spirometry | 2 | 2024 | 257 | 0.200 |
Why?
| | Oocytes | 2 | 2020 | 171 | 0.200 |
Why?
| | Body Mass Index | 6 | 2019 | 2269 | 0.200 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1211 | 0.200 |
Why?
| | Aging | 4 | 2008 | 1770 | 0.190 |
Why?
| | Benchmarking | 1 | 2023 | 175 | 0.190 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 5078 | 0.190 |
Why?
| | Prospective Studies | 9 | 2023 | 7150 | 0.190 |
Why?
| | Markov Chains | 3 | 2017 | 117 | 0.190 |
Why?
| | Monte Carlo Method | 3 | 2017 | 143 | 0.190 |
Why?
| | Respiratory Function Tests | 2 | 2024 | 581 | 0.190 |
Why?
| | Antiviral Agents | 2 | 2024 | 719 | 0.180 |
Why?
| | Disability Evaluation | 4 | 2018 | 283 | 0.180 |
Why?
| | Doxycycline | 2 | 2011 | 59 | 0.170 |
Why?
| | Weight Gain | 2 | 2022 | 510 | 0.170 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 16 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 95 | 0.170 |
Why?
| | Oocyte Donation | 1 | 2020 | 4 | 0.170 |
Why?
| | Healthy Aging | 1 | 2021 | 34 | 0.170 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 91 | 0.170 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 5 | 0.170 |
Why?
| | Memory, Episodic | 1 | 2021 | 48 | 0.170 |
Why?
| | Prescription Drugs | 1 | 2022 | 109 | 0.170 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 35 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 190 | 0.170 |
Why?
| | Apomorphine | 3 | 2009 | 5 | 0.160 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 51 | 0.160 |
Why?
| | Fractals | 1 | 2019 | 8 | 0.160 |
Why?
| | Menstruation | 2 | 1991 | 43 | 0.160 |
Why?
| | Internet | 2 | 2018 | 620 | 0.160 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 21 | 0.160 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2734 | 0.160 |
Why?
| | Radial Nerve | 1 | 1999 | 9 | 0.160 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 23 | 0.160 |
Why?
| | Machine Learning | 1 | 2024 | 441 | 0.160 |
Why?
| | Human Growth Hormone | 2 | 2014 | 45 | 0.160 |
Why?
| | Health Status | 3 | 2010 | 756 | 0.160 |
Why?
| | Cohort Studies | 6 | 2024 | 5423 | 0.150 |
Why?
| | Astrocytes | 1 | 2021 | 197 | 0.150 |
Why?
| | Quality of Life | 5 | 2018 | 2694 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1196 | 0.150 |
Why?
| | Hip Fractures | 1 | 2019 | 83 | 0.150 |
Why?
| | Vital Capacity | 1 | 2019 | 290 | 0.150 |
Why?
| | Datasets as Topic | 1 | 2018 | 109 | 0.150 |
Why?
| | Bibliometrics | 1 | 2018 | 53 | 0.150 |
Why?
| | Case-Control Studies | 5 | 2021 | 3383 | 0.140 |
Why?
| | Sheep, Domestic | 1 | 2017 | 34 | 0.140 |
Why?
| | Regression Analysis | 2 | 2019 | 994 | 0.140 |
Why?
| | Contraception | 2 | 1991 | 153 | 0.140 |
Why?
| | Adolescent | 14 | 2024 | 20409 | 0.140 |
Why?
| | Eligibility Determination | 2 | 2008 | 63 | 0.140 |
Why?
| | Algorithms | 3 | 2017 | 1614 | 0.140 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 1 | 0.140 |
Why?
| | Rhinitis | 2 | 2010 | 152 | 0.140 |
Why?
| | Medically Uninsured | 2 | 2008 | 127 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 711 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2018 | 103 | 0.130 |
Why?
| | Premature Birth | 1 | 2020 | 317 | 0.130 |
Why?
| | Psychomotor Performance | 3 | 2009 | 312 | 0.130 |
Why?
| | Lactation | 1 | 2018 | 175 | 0.130 |
Why?
| | Family Planning Services | 2 | 2008 | 87 | 0.130 |
Why?
| | Hypothyroidism | 2 | 2007 | 66 | 0.130 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 100 | 0.130 |
Why?
| | Pregnancy | 8 | 2023 | 6412 | 0.130 |
Why?
| | Double-Blind Method | 7 | 2011 | 1873 | 0.130 |
Why?
| | Affect | 3 | 2008 | 289 | 0.130 |
Why?
| | Endoscopy | 2 | 2010 | 290 | 0.130 |
Why?
| | Sinusitis | 2 | 2010 | 211 | 0.130 |
Why?
| | Reproducibility of Results | 2 | 2017 | 3081 | 0.130 |
Why?
| | Antibodies | 1 | 2018 | 398 | 0.130 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 169 | 0.130 |
Why?
| | Dietary Fats | 1 | 2018 | 298 | 0.130 |
Why?
| | Low Back Pain | 1 | 2018 | 105 | 0.130 |
Why?
| | Antibodies, Neutralizing | 3 | 2022 | 265 | 0.130 |
Why?
| | Immunologic Memory | 1 | 2018 | 349 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 342 | 0.130 |
Why?
| | Models, Animal | 1 | 2017 | 375 | 0.120 |
Why?
| | Personnel Selection | 1 | 2016 | 70 | 0.120 |
Why?
| | Recovery of Function | 2 | 2010 | 644 | 0.120 |
Why?
| | Otolaryngology | 1 | 2016 | 88 | 0.120 |
Why?
| | Brain | 5 | 2023 | 2675 | 0.120 |
Why?
| | Patient Dropouts | 1 | 2015 | 64 | 0.120 |
Why?
| | Cross-Over Studies | 5 | 2009 | 522 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 212 | 0.110 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 147 | 0.110 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 11 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 13 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 127 | 0.110 |
Why?
| | Menstrual Cycle | 3 | 2011 | 121 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 137 | 0.110 |
Why?
| | Breast Feeding | 1 | 2018 | 424 | 0.110 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 203 | 0.110 |
Why?
| | Brain Ischemia | 1 | 2017 | 321 | 0.110 |
Why?
| | Analysis of Variance | 5 | 2009 | 1286 | 0.110 |
Why?
| | Dementia | 2 | 2008 | 225 | 0.110 |
Why?
| | Health Care Costs | 1 | 2017 | 366 | 0.110 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 206 | 0.110 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 763 | 0.110 |
Why?
| | Biomarkers | 4 | 2021 | 3968 | 0.110 |
Why?
| | Antibody Formation | 2 | 2022 | 291 | 0.110 |
Why?
| | Secretory Rate | 1 | 2013 | 16 | 0.100 |
Why?
| | Health Policy | 2 | 2024 | 350 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1098 | 0.100 |
Why?
| | Interviews as Topic | 3 | 2010 | 707 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 168 | 0.100 |
Why?
| | Electronics | 1 | 2013 | 74 | 0.100 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 321 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 211 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1500 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 439 | 0.100 |
Why?
| | Adenoma | 1 | 2014 | 211 | 0.100 |
Why?
| | Medical Records | 1 | 2013 | 171 | 0.100 |
Why?
| | Treatment Outcome | 8 | 2024 | 10232 | 0.100 |
Why?
| | Age Factors | 8 | 2018 | 3150 | 0.100 |
Why?
| | Wakefulness | 1 | 2013 | 120 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 385 | 0.090 |
Why?
| | Urban Health | 2 | 2009 | 79 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 529 | 0.090 |
Why?
| | Memory | 3 | 2008 | 242 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2017 | 4891 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 532 | 0.090 |
Why?
| | Statistics as Topic | 2 | 2009 | 305 | 0.090 |
Why?
| | Cognition | 3 | 2008 | 1125 | 0.090 |
Why?
| | Insulin | 1 | 2022 | 2313 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 78 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 514 | 0.090 |
Why?
| | Amenorrhea | 1 | 2011 | 27 | 0.090 |
Why?
| | Dopamine Agonists | 2 | 2008 | 39 | 0.090 |
Why?
| | Risk Assessment | 2 | 2017 | 3255 | 0.090 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 31 | 0.090 |
Why?
| | Birth Certificates | 1 | 2010 | 10 | 0.090 |
Why?
| | Estrone | 1 | 2010 | 37 | 0.090 |
Why?
| | Birth Rate | 2 | 2020 | 26 | 0.090 |
Why?
| | Cytokines | 2 | 2015 | 2018 | 0.090 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 41 | 0.090 |
Why?
| | Automobile Driving | 2 | 2010 | 140 | 0.090 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 15 | 0.090 |
Why?
| | Live Birth | 2 | 2020 | 57 | 0.080 |
Why?
| | Diet | 1 | 2018 | 1211 | 0.080 |
Why?
| | Pregnancy Rate | 2 | 2020 | 59 | 0.080 |
Why?
| | Geographic Information Systems | 2 | 2010 | 42 | 0.080 |
Why?
| | Myocardial Infarction | 1 | 2017 | 1018 | 0.080 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 76 | 0.080 |
Why?
| | Thyroxine | 2 | 2007 | 60 | 0.080 |
Why?
| | Cities | 1 | 2010 | 105 | 0.080 |
Why?
| | United States | 6 | 2020 | 13865 | 0.080 |
Why?
| | Registries | 1 | 2017 | 1902 | 0.080 |
Why?
| | Sex Factors | 5 | 2018 | 1966 | 0.080 |
Why?
| | Personality | 1 | 2011 | 124 | 0.080 |
Why?
| | Abortion, Induced | 2 | 2008 | 99 | 0.080 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 8 | 0.080 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 37 | 0.080 |
Why?
| | Telecommunications | 1 | 2009 | 20 | 0.080 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 75 | 0.080 |
Why?
| | Independent Living | 1 | 2010 | 96 | 0.080 |
Why?
| | Mortality | 1 | 2011 | 306 | 0.080 |
Why?
| | Progesterone | 3 | 2015 | 244 | 0.080 |
Why?
| | Rural Health | 1 | 2009 | 71 | 0.080 |
Why?
| | Postmenopause | 1 | 2010 | 349 | 0.070 |
Why?
| | Drug Interactions | 2 | 2007 | 397 | 0.070 |
Why?
| | Exercise | 3 | 2010 | 1931 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 1983 | 0.070 |
Why?
| | Child, Preschool | 4 | 2018 | 10499 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 9 | 0.070 |
Why?
| | Foot | 1 | 2009 | 89 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 83 | 0.070 |
Why?
| | Ointments | 1 | 2007 | 24 | 0.070 |
Why?
| | Povidone-Iodine | 1 | 2007 | 11 | 0.070 |
Why?
| | Vaccinia | 1 | 2007 | 21 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 23 | 0.070 |
Why?
| | Life Change Events | 1 | 2009 | 149 | 0.070 |
Why?
| | Vaccinia virus | 1 | 2007 | 42 | 0.070 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 45 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 267 | 0.070 |
Why?
| | Disease Progression | 3 | 2015 | 2628 | 0.070 |
Why?
| | Population Surveillance | 1 | 2010 | 440 | 0.070 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 34 | 0.070 |
Why?
| | Counseling | 1 | 2010 | 383 | 0.070 |
Why?
| | Atrophy | 1 | 2007 | 169 | 0.070 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 12 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 119 | 0.070 |
Why?
| | Awareness | 1 | 2007 | 99 | 0.070 |
Why?
| | Time Perception | 1 | 2007 | 28 | 0.070 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 139 | 0.070 |
Why?
| | Antigens, Viral | 1 | 2007 | 179 | 0.070 |
Why?
| | Movement | 1 | 2009 | 266 | 0.070 |
Why?
| | Internship and Residency | 1 | 2016 | 1049 | 0.070 |
Why?
| | Albumins | 1 | 2007 | 104 | 0.070 |
Why?
| | Tremor | 1 | 2007 | 60 | 0.060 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 213 | 0.060 |
Why?
| | Suicide, Attempted | 1 | 2009 | 356 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 1918 | 0.060 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 132 | 0.060 |
Why?
| | Infant | 3 | 2010 | 9005 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 566 | 0.060 |
Why?
| | Paroxetine | 1 | 2005 | 10 | 0.060 |
Why?
| | Treatment Failure | 2 | 2022 | 339 | 0.060 |
Why?
| | Animals | 6 | 2023 | 35334 | 0.060 |
Why?
| | Attitude to Health | 1 | 2008 | 432 | 0.060 |
Why?
| | Administration, Oral | 1 | 2007 | 783 | 0.060 |
Why?
| | Neurologic Examination | 2 | 2008 | 112 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1842 | 0.060 |
Why?
| | Health Promotion | 1 | 2010 | 716 | 0.060 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2024 | 74 | 0.060 |
Why?
| | Sexual Behavior | 1 | 2008 | 481 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 567 | 0.050 |
Why?
| | Child | 5 | 2018 | 20932 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2024 | 977 | 0.050 |
Why?
| | Likelihood Functions | 2 | 2017 | 137 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4403 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 195 | 0.050 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 11 | 0.050 |
Why?
| | Family | 1 | 2008 | 645 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 47 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 818 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 76 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 98 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 686 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 734 | 0.050 |
Why?
| | Physical Fitness | 1 | 2004 | 202 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 400 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 545 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 2 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 73 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1257 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 13 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 816 | 0.050 |
Why?
| | Physical Examination | 2 | 2018 | 233 | 0.050 |
Why?
| | Acids | 1 | 2002 | 16 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 124 | 0.050 |
Why?
| | Odds Ratio | 3 | 2010 | 1018 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3392 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2002 | 64 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1708 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 761 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 157 | 0.040 |
Why?
| | Neuroimaging | 1 | 2023 | 279 | 0.040 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 167 | 0.040 |
Why?
| | Puberty | 1 | 2002 | 143 | 0.040 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 109 | 0.040 |
Why?
| | Leptin | 1 | 2002 | 222 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 10 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 16 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 276 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 201 | 0.040 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2101 | 0.040 |
Why?
| | Blastocyst | 1 | 2020 | 45 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2020 | 32 | 0.040 |
Why?
| | Fasting | 1 | 2002 | 265 | 0.040 |
Why?
| | Prostaglandins | 1 | 2000 | 94 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 115 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 2013 | 0.040 |
Why?
| | Vaccination | 2 | 2024 | 1348 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 220 | 0.040 |
Why?
| | Depression | 1 | 2008 | 1321 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1283 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 96 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 1950 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 87 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 851 | 0.030 |
Why?
| | Depressive Disorder, Major | 1 | 2001 | 344 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2000 | 365 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.030 |
Why?
| | Milk | 1 | 2018 | 122 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 422 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2008 | 316 | 0.030 |
Why?
| | Viruses | 1 | 2018 | 100 | 0.030 |
Why?
| | Incidence | 2 | 2017 | 2643 | 0.030 |
Why?
| | Electromyography | 1 | 1999 | 379 | 0.030 |
Why?
| | Biostatistics | 1 | 2017 | 16 | 0.030 |
Why?
| | Psychological Tests | 1 | 2018 | 135 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 68 | 0.030 |
Why?
| | Thyrotropin | 2 | 2007 | 107 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 239 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1270 | 0.030 |
Why?
| | Drug Combinations | 2 | 2011 | 329 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 872 | 0.030 |
Why?
| | Health Surveys | 2 | 2009 | 493 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2450 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 836 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 766 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 230 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 197 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 60 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1422 | 0.030 |
Why?
| | Systole | 1 | 2015 | 190 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 41 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 105 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1203 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 246 | 0.030 |
Why?
| | Risk | 1 | 2017 | 857 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 515 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 919 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 215 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 594 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 179 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 109 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 696 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 647 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3058 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4073 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 368 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5468 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 850 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2008 | 1011 | 0.030 |
Why?
| | Estrogens | 1 | 2015 | 346 | 0.030 |
Why?
| | Follicular Phase | 2 | 2004 | 38 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 427 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 625 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 300 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 731 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 572 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1491 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 3772 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 22 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 105 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 59 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 61 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5769 | 0.020 |
Why?
| | Amides | 1 | 2010 | 91 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 538 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 165 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 722 | 0.020 |
Why?
| | Income | 1 | 2010 | 187 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 162 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 795 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1058 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 104 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 16 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 10 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 424 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 180 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 35 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 174 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 35 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 13 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 269 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 16 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 840 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 57 | 0.020 |
Why?
| | Employment | 1 | 2010 | 167 | 0.020 |
Why?
| | Parity | 1 | 1988 | 120 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 8 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 20 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 25 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 34 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 395 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 68 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 204 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 48 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 162 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 89 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 148 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 525 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 66 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 469 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 481 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 157 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 45 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 43 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 5429 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 76 | 0.020 |
Why?
| | Research | 1 | 2010 | 419 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 55 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 456 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 242 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 92 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 157 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 90 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 495 | 0.020 |
Why?
| | Safety | 1 | 2008 | 335 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 95 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2010 | 636 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 533 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 320 | 0.020 |
Why?
| | Mental Recall | 1 | 2007 | 191 | 0.020 |
Why?
| | Dopamine Agents | 1 | 2005 | 16 | 0.010 |
Why?
| | Virus Diseases | 1 | 2007 | 210 | 0.010 |
Why?
| | Vestibular Diseases | 1 | 2005 | 24 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 631 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1548 | 0.010 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 42 | 0.010 |
Why?
| | Dizziness | 1 | 2005 | 80 | 0.010 |
Why?
| | Self Efficacy | 1 | 2008 | 377 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 476 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2007 | 255 | 0.010 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 84 | 0.010 |
Why?
| | Length of Stay | 1 | 2009 | 1132 | 0.010 |
Why?
| | Diet Records | 1 | 2004 | 80 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1722 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1043 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 59 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 531 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 318 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 169 | 0.010 |
Why?
| | Skin | 1 | 2007 | 724 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 1067 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 807 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1368 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 286 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 27 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 5 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 2143 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 25 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 38 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 167 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 33 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 48 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 89 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 104 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 147 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 462 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 663 | 0.010 |
Why?
| | Periodicity | 1 | 2000 | 57 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 306 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 44 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 2729 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 2 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 22 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 392 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 507 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2271 | 0.010 |
Why?
| | Fever | 1 | 2000 | 298 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1235 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 688 | 0.010 |
Why?
| | Mice | 1 | 2007 | 16973 | 0.010 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|